Taysha gene therapies announces presentations at the upcoming 25th annual meeting of the american society of gene & cell therapy

Dallas, may 10, 2022 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced oral and poster presentations and a company-sponsored symposium at the upcoming 25th annual meeting of the american society of gene & cell therapy (asgct) taking place in washington, d.c. from may 16-19, 2022.
TSHA Ratings Summary
TSHA Quant Ranking